Mazdutide: The Dual GLP-1/Glucagon Drug Approved in China
While Western attention focuses on retatrutide and CagriSema, a dual glucagon/GLP-1 agonist has already been approved - just not in the US. Here is what mazdutide achieved in Phase 3, and why approval elsewhere does not mean you can get it.
Last updated: August 3, 2026
Not Available in the United States
Mazdutide is approved by China's National Medical Products Administration, not the FDA. It is not available by prescription in the US, and personal importation of prescription medication is generally not permitted under federal law. Approval in one country does not make a drug obtainable in another.
Quick Answer
Mazdutide is the first dual glucagon (GCG) and GLP-1 receptor agonist to receive approval for chronic weight management anywhere, cleared by China's NMPA as an adjunct to a reduced-calorie diet for adults with overweight or obesity. It is developed by Innovent Biologics.
The pivotal GLORY-1 Phase 3 trial was published in the New England Journal of Medicine, showing that once-weekly mazdutide at 4 mg or 6 mg over 32 weeks produced clinically relevant weight reductions in Chinese adults with overweight or obesity.
Higher-dose data is more striking: the 9 mg group achieved a mean weight reduction of 18.55% versus 3.02% on placebo, and in a separate analysis 81.7% of participants achieved at least 5% weight loss after 24 weeks, against none on placebo.
What Mazdutide Is
Mazdutide is a once-weekly injectable developed by Innovent Biologics, and it holds a genuine first: the first dual GCG/GLP-1 receptor agonist approved for weight management, cleared by China's National Medical Products Administration.
It activates two receptors:
- GLP-1 receptor - the familiar mechanism, reducing appetite and slowing gastric emptying.
- Glucagon receptor - increasing energy expenditure and promoting fat breakdown in the liver.
The approval covers chronic weight management as an adjunct to a reduced-calorie diet in adults with overweight or obesity. Innovent has also reported glucose-lowering effects and reductions in waist circumference.
Why Adding Glucagon Works
Adding glucagon to a weight loss drug sounds backwards, because glucagon raises blood sugar - it is the hormone that opposes insulin. Deliberately activating it in a metabolic drug seems like the wrong direction.
It works because the two mechanisms address different sides of the energy balance equation:
| Receptor | Effect | Side of the Equation |
|---|---|---|
| GLP-1 | Reduces appetite, slows gastric emptying | Energy in |
| Glucagon | Increases energy expenditure, promotes hepatic fat breakdown | Energy out |
The glucose-raising effect of glucagon is offset by the powerful glucose-lowering effect of GLP-1 activation, leaving the increased energy expenditure as the net benefit. It only works because the two are combined.
This is the same logic behind survodutide and retatrutide. Survodutide is a GLP-1/glucagon dual agonist; retatrutide adds GIP for a triple agonist. Mazdutide's significance is that it got a glucagon-containing drug across the regulatory line first, in at least one major market - validating the mechanism commercially rather than only in trials. See our guides to survodutide and retatrutide.
GLORY-1 and the Dose Data
The pivotal Phase 3 trial, GLORY-1, was published in the New England Journal of Medicine.
| Dose and Duration | Result |
|---|---|
| 4 mg or 6 mg, 32 weeks | Clinically relevant reductions in body weight; significant versus placebo at both doses |
| 9 mg | Mean weight reduction 18.55% vs 3.02% on placebo |
| 9 mg, 24 weeks (higher BMI group) | 81.7% achieved at least 5% weight loss; no placebo participants did |
| Phase 2, up to 6 mg, 24 weeks | Safe, with robust weight reduction in Chinese adults with overweight or obesity |
The 81.7% figure against 0% on placebo is the most striking number here. Response rates that clean are uncommon, though the 24-week window and specific population matter for interpretation.
At 18.55%, the 9 mg dose sits between semaglutide (roughly 15%) and tirzepatide (20-22%) - competitive, though not a leap beyond what is already approved in the US.
Mazdutide vs Survodutide vs Retatrutide
| Drug | Mechanism | Weight Loss | Status |
|---|---|---|---|
| Mazdutide | GLP-1 + glucagon | 18.55% at 9 mg | Approved in China |
| Survodutide | GLP-1 + glucagon | Up to 16.6% at 76 weeks (Phase 3) | Investigational |
| Retatrutide | GLP-1 + GIP + glucagon | 28.3% at 80 weeks | Investigational |
| Tirzepatide (approved US) | GLP-1 + GIP | 20-22% | Approved |
Retatrutide leads on raw percentage, but note the durations - mazdutide's 18.55% came over a shorter window than retatrutide's 80-week 28.3%. Cross-trial comparison across different populations and durations is unreliable, as our head-to-head guide explains.
A Caveat About the Trial Population
This is worth stating plainly rather than glossing over: the pivotal mazdutide trials studied Chinese adults.
That is not a criticism - it is entirely appropriate for a drug seeking Chinese approval, and it addresses a population historically underrepresented in obesity trials. But it does affect how the numbers transfer:
- Baseline BMI differs. Obesity thresholds and average starting weights differ between Chinese and Western trial populations, and percentage weight loss can behave differently depending on starting point.
- Genetic and dietary context varies, both of which influence metabolic drug response.
- Regulatory standards differ between the NMPA and FDA, though both are serious agencies with substantive review processes.
Practically: mazdutide's results are real and its approval is genuine, but you should not assume an 18.55% figure would replicate identically in a US trial population. Any FDA submission would require trials in relevant populations.
Will It Come to the US?
Unknown. Approval in China does not create a pathway to US availability - a separate FDA submission with appropriate trial data would be required, and no timeline has been announced.
Do not attempt to import it. Personal importation of prescription medication into the US is generally not permitted under federal law. Beyond the legal question, importing an injectable brings real risks: no guarantee of cold-chain integrity in transit, no US prescriber managing your titration or monitoring for pancreatitis and gallbladder complications, and no recourse if the product is not what it claims.
Websites offering to ship prescription GLP-1s internationally are frequently operating outside any regulatory framework.
The more useful takeaway is what mazdutide signals: glucagon-containing dual agonists work well enough to clear a major regulator. That is encouraging for survodutide and retatrutide, which use the same mechanism and are being developed for Western markets.
Meanwhile, tirzepatide at 20-22% is approved and available in the US, and self-pay pricing now starts at $299/month for vials. See our Zepbound cost guide and cash-pay options.
Frequently Asked Questions
What is mazdutide?
A once-weekly injectable from Innovent Biologics, and the first dual glucagon and GLP-1 receptor agonist approved for chronic weight management - cleared by China's National Medical Products Administration as an adjunct to a reduced-calorie diet for adults with overweight or obesity. It activates the GLP-1 receptor to reduce appetite and the glucagon receptor to increase energy expenditure.
How much weight loss does mazdutide produce?
The 9 mg group achieved a mean weight reduction of 18.55% versus 3.02% on placebo. In a separate 24-week analysis of a higher-BMI group, 81.7% of mazdutide participants achieved at least 5% weight loss while no placebo participants did. The pivotal GLORY-1 Phase 3 trial, published in NEJM, showed clinically relevant reductions at 4 mg and 6 mg over 32 weeks.
Can I get mazdutide in the US?
No. It is approved by China's NMPA, not the FDA, and is not available by prescription in the United States. Personal importation of prescription medication is generally not permitted under federal law, and importing injectables carries real risks around cold-chain integrity, lack of prescriber monitoring, and no recourse if the product is not what it claims.
Is mazdutide better than tirzepatide?
They have never been compared head-to-head, and cross-trial comparison is unreliable. Mazdutide reported 18.55% at 9 mg; tirzepatide produces 20-22% in its own trials. They also use different mechanisms - mazdutide combines GLP-1 with glucagon, tirzepatide with GIP. Tirzepatide is approved and available in the US; mazdutide is not.
How is mazdutide different from survodutide?
Both are dual GLP-1 and glucagon receptor agonists using the same mechanism. The difference is development status and geography - mazdutide is approved in China, while survodutide remains investigational, having reported up to 16.6% mean weight loss at 76 weeks in Phase 3 as of April 2026. Mazdutide getting across the regulatory line first is meaningful validation for the whole glucagon-containing class.
Why does adding glucagon help weight loss?
Glucagon increases energy expenditure and promotes fat breakdown in the liver, addressing the energy-out side of the equation while GLP-1 reduces intake. It sounds contradictory because glucagon raises blood sugar - but the powerful glucose-lowering effect of GLP-1 activation offsets that, leaving increased energy expenditure as the net benefit. It only works because the two are combined in one molecule.
Do the Chinese trial results apply to me?
Not necessarily identically. The pivotal trials studied Chinese adults, which is appropriate for Chinese approval and addresses an underrepresented population, but baseline BMI, genetic factors, and dietary context all differ between trial populations and influence how percentage weight loss translates. Any FDA submission would require trials in relevant populations.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Mazdutide is not approved by the FDA and is not available by prescription in the United States. Nothing here should be interpreted as encouragement to import prescription medication, which is generally not permitted under federal law. Clinical trial figures come from studies conducted in Chinese adult populations and may not translate directly to other populations; they represent group averages and do not predict individual results. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. HealthyPound may receive compensation from affiliate partners mentioned in this article. See our affiliate disclosure and full medical disclaimer.